IP Library Patent Application 12399702
Patent Application
App. No. 12/399,702

DIAMINE DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/399,702
Abstract

The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.

Claims (6)

1 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetralhydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (I), or a salt thereof:

2 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (II):

3 . A composition comprising a pharmaceLitically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (III):

4 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (IV), or a salt thereof:

5 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (V):

6 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (VI):

Assignments (1)
MERGER Recorded Feb 10, 2010
From: DAIICHI PHARMACEUTICAL CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 023915/0622 →